Bold statement: setbacks keep stacking for Christophe Laporte and Visma-Lease a Bike, but the story isn’t over yet. Here’s a fresh, expanded retelling that preserves every key detail while boosting clarity and accessibility. And yes, we’ll spotlight the softer edges of controversy to invite thoughtful discussion.
Visma-Lease a Bike, the UCI WorldTour squad, may have Wout van Aert back in action at the Ename Samyn Classic after recovering from illness. Yet another setback has hit the Dutch-registered team: Christophe Laporte has withdrawn from the cobbled classic. The team announced on the morning of the race that Laporte was “not feeling 100% fit” following Opening Weekend, forcing him to skip the 203.8km event.
Laporte had started the season in strong form, most notably taking a stage win at the Vuelta a Andalucía (Andalucía). That result suggested he was returning to top form after a difficult 2025, during which he battled a long-running cytomegalovirus infection that severely disrupted his Classics program and his Tour de France campaign.
The latest race setback compounds what has already been a trying period for Laporte and for Visma-Lease a Bike, who have faced a run of misfortune and timing issues as they push to regain momentum ahead of the central Spring Classics.
After a late-season remarking return, Laporte had looked to be on track toward regaining his former level in 2026. He even produced a notable performance at Omloop Het Nieuwsblad, saying, “I’m pleased that I was still able to deliver a strong result for the team today. After an unlucky season last year, it’s nice to show myself again in races like this.” The unfortunate illness interrupting him at Samyn adds another twist to a comeback that has already seen him ride through a rough patch.
Analysts and fans will be watching closely to determine whether this is merely a temporary blip or an early warning sign of lingering fitness concerns as the Spring campaign approaches. The timing isn’t ideal for Laporte, whose presence is valuable both for leadership and for sprinting options on a demanding cobbled course.
Controversy and discussion point: some observers might argue that the ongoing health challenges raise questions about the team’s training load, medical decisions, and race selection during a sensitive comeback year. Others could contend that a deliberate, cautious return is prudent given the severity of last year’s illness. Do you think teams should prioritize long-term health over early-season results, or is there pressure to push athletes back into competition sooner than is optimal?
For more updates on Spring Classics coverage, including Milan-San Remo, Paris-Roubaix, and the Tour of Flanders, consider a Cyclingnews subscription for access to breaking news, reports, and expert analysis.
